BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

Rhea-AI Summary

BioLineRx (NASDAQ: BLRX) will release unaudited third quarter results for the period ended September 30, 2025 on Monday, November 24, 2025 before U.S. markets open.

Management will host a conference call on November 24, 2025 at 8:30 a.m. EST with remarks by Philip Serlin, CEO. U.S. dial-in is +1-888-281-1167; international dial-in is +972-3-918-0685. A live webcast and replay will be available on the company website; the replay will be posted about two hours after the call and a dial-in replay runs until November 26, 2025 (+1-888-295-2634 U.S., +972-3-925-5904 international).

News Market Reaction

-5.31% 1.7x vol

5 alerts

-5.31% News Effect

+14.3% Peak in 17 hr 59 min

-$796K Valuation Impact

$14M Market Cap

1.7x Rel. Volume

On the day this news was published, BLRX declined 5.31%, reflecting a notable negative market reaction. Argus tracked a peak move of +14.3% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $796K from the company's valuation, bringing the market cap to $14M at that time. Trading volume was above average at 1.7x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Management to Hold Conference Call at 8:30 a.m. EST

TEL AVIV, Israel, Nov. 18, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2025 on Monday, November 24, 2025, before the U.S. markets open.

The Company will host a conference call at 8:30 a.m. EST featuring remarks by Philip Serlin, Chief Executive Officer.

To access the conference call, please dial +1-888-281-1167 from the U.S. or +972-3-918-0685 internationally. A live webcast and a replay of the call can be accessed through the event page on the Company's website. Please allow extra time prior to the call to visit the site and download any necessary software to listen to the live broadcast. The call replay will be available approximately two hours after completion of the live conference call. A dial-in replay of the call will be available until November 26, 2025; please dial +1-888-295-2634 from the US or +972-3-925-5904 internationally.

About BioLineRx

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is a biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases. The Company's first approved product is APHEXDA® (motixafortide), with an indication in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma, and is commercialized by Ayrmid Ltd. (globally, except Asia) and Gloria Biosciences (in Asia). BioLineRx has retained rights to develop motixafortide in metastatic pancreatic cancer (PDAC) and has a Phase 2b PDAC trial currently ongoing under a collaboration with Columbia University.

In addition, BioLineRx has established a joint venture with Hemispherian AS to develop GLIX1, a first-in-class, oral, small molecule targeting DNA damage response in glioblastoma and other solid tumors, for which a Phase 1/2a clinical trial is planned to be initiated in the first quarter of 2026.

Learn more about who we are, what we do, and how we do it at www.biolinerx.com, or on LinkedIn.

CONTACTS:

United States
Irina Koffler
LifeSci Advisors, LLC
IR@biolinerx.com

Israel
Moran Meir
LifeSci Advisors, LLC
moran@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/2154863/BioLineRx_Ltd_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/biolinerx-to-report-third-quarter-2025-results-on-november-24-2025-302618423.html

SOURCE BioLineRx Ltd.

FAQ

When will BioLineRx (BLRX) report Q3 2025 results?

BioLineRx will release unaudited Q3 2025 results on Monday, November 24, 2025 before U.S. markets open.

What time is the BioLineRx (BLRX) Q3 2025 conference call and who will speak?

The conference call is scheduled for 8:30 a.m. EST on November 24, 2025 with remarks by Philip Serlin, CEO.

How can investors access the BioLineRx (BLRX) November 24, 2025 webcast and replay?

A live webcast and replay will be available on BioLineRx's event page; the replay will be posted about two hours after the call.

What dial-in numbers should U.S. and international listeners use for the BLRX call?

U.S. dial-in: +1-888-281-1167; international: +972-3-918-0685. Dial-in replay: U.S +1-888-295-2634, international +972-3-925-5904.

How long will the phone replay of the BioLineRx (BLRX) call be available?

The dial-in replay will be available until November 26, 2025.